

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PROPOSED AMENDMENTS TO THE SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in relation to the proposed amendments to the second amended and restated memorandum and articles of association of Company (the “**Second Amended and Restated Memorandum and Articles of Association**”).

On 1 January 2022, the Listing Rules were amended by, among others, adopting a uniform set of 14 core standards for shareholder protections for issuers regardless of their place of incorporation set out in Appendix 3 to the Listing Rules. Furthermore, the Company proposes to modernize and provide flexibility to the Company in relation to the conduct of general meetings. The board of directors of the Company (the “**Board**”) proposes to make certain amendments to the Second Amended and Restated Memorandum and Articles of Association to conform to the said core standards for shareholder protections, to allow a general meeting to be held as an electronic meeting (also referred to as virtual general meeting) or a hybrid meeting and to incorporate certain housekeeping changes. The Board also proposes to adopt the third amended and restated memorandum and articles of association of Company (the “**Third Amended and Restated Memorandum and Articles of Association**”) in substitution for, and to the exclusion of, the existing Second Amended and Restated Memorandum and Articles of Association.

The proposed amendments to the Second Amended and Restated Memorandum and Articles of Association shall be subject to the passing of a special resolution by the shareholders of the Company at the forthcoming annual general meeting of the Company to be held on or before 30 June 2023 (the “AGM”). A circular containing, among others, details of the proposed amendments to the Second Amended and Restated Memorandum and Articles of Association and a notice convening the AGM will be despatched to the Company’s shareholders as soon as practicable.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 31 March 2023

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Chin Yu; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao and Mr. Ng Ming Kwan.